MUSTANG BIO INC. news, videos and press releases - Page 3
For more news please use our advanced search feature.
MUSTANG BIO INC. - More news...
MUSTANG BIO INC. - More news...
- Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients
- Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
- Mustang Bio to Participate in Three January 2022 Virtual Investor Conferences
- Mustang Bio Added to the NASDAQ Biotechnology Index
- Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
- Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
- Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
- Mustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy with Curative Potential for RAG1 Severe Combined Immunodeficiency
- Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting
- Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy for Treatment of B-cell non-Hodgkin Lymphomas
- Mustang Bio to Participate in Chardan’s Virtual 5th Annual Genetic Medicines Conference
- Mustang Bio Announces MB-101 (IL13Rα2‐targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences
- Mustang Bio to Participate in Three September 2021 Investor Conferences
- Mustang Bio Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights
- Mustang Bio Collaborates with Mayo Clinic on Novel CAR T Technology
- Mustang Bio Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
- Mustang Bio Awarded Massachusetts Life Sciences Center Tax Incentive
- Mustang Bio to Present at the Raymond James Human Health Innovation Conference
- Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
- Mustang Bio to Host Key Opinion Leader Webinar on MB-106 CD20-Targeted CAR T for the Treatment of High-Risk B-Cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
- Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
- Mustang Bio Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
- Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress
- Mustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy
- Mustang Bio to Participate in Chardan’s 5th Annual Genetic Medicines Manufacturing Summit
- Mustang Bio Reports Full-Year 2020 Financial Results and Recent Corporate Highlights
- Mustang Bio to Participate in Three March 2021 Virtual Investor Conferences
- Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®
- Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)
- Mustang Bio to Participate in Three January 2021 Virtual Investor Conferences
